Evidence map›Paper›PMID 30593278›Full record

ArticleBMC biology2018

BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.

Matthew A Coelho, Songyuan Li, Luna Simona Pane, Mike Firth, Giovanni Ciotta, Jonathan D Wrigley, Maria Emanuela Cuomo, Marcello Maresca, Benjamin J M Taylor

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. HAMMER: Hairpin-based APOBEC3A-mediated mRNA editing reporter.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Rescue of hearing by adenine base editing in a humanized mouse model of Usher syndrome type 1F.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  11. Enrichment strategies to enhance genome editing.Journal of biomedical science · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 4 countries.

Matthew A CoelhoDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK. Matthew.Coelho@astrazeneca.com.
Songyuan LiDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Luna Simona PaneDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Mike FirthDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Giovanni CiottaDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Jonathan D WrigleyDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Maria Emanuela CuomoDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Marcello MarescaDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Benjamin J M TaylorDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK. Benjamin.Taylor@astrazeneca.com.ORCID 0000-0001-6101-3786
AstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBase Editing is a precise genome editing method that uses a deaminase-Cas9 fusion protein to mutate cytidine to thymidine in target DNA in situ without the generation of a double-strand break. However, the efficient enrichment of genetically modified cells using this technique is limited by the ability to detect such events.

resultsWe have developed a Base Editing FLuorescent Activity REporter (BE-FLARE), which allows for the enrichment of cells that have undergone editing of target loci based on a fluorescence shift from BFP to GFP. We used BE-FLARE to evaluate the editing efficiency of APOBEC3A and APOBEC3B family members as alternatives deaminase domains to the rat APOBEC1 domain used in base editor 3 (BE3). We identified human APOBEC3A and APOBEC3B as highly efficient cytidine deaminases for base editing applications with unique properties.

conclusionsUsing BE-FLARE to report on the efficiency and precision of editing events, we outline workflows for the accelerated generation of genetically engineered cell models and the discovery of alternative base editors.

Indexed as

AnimalsAPOBEC-1 DeaminaseCytidine DeaminaseGene EditingGenetic EngineeringHumansMinor Histocompatibility AntigensProteinsRatsAPOBEC-1 DeaminaseApobec1 protein, ratAPOBEC3A protein, humanAPOBEC3B protein, humanCytidine DeaminaseMinor Histocompatibility AntigensProteinsAPOBECBase editingCRISPR/Cas9Fluorescent reporterGene editing

Identifiers

PMID30593278
PMCPMC6309101
OpenAlexW2907584832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.